Arthritis Medication Shows Promise in Treating Severe Alopecia

Over 50 percent of participants with severe alopecia areata regained significant scalp hair after taking upadacitinib in recent clinical trials. By blocking the immune signals that trigger follicle attacks, this arthritis medication offers a potential breakthrough for patients who have exhausted existing treatment options for the autoimmune condition.

Editorial·September 8, 2026·reads: 2,643

Arthritis Medication Shows Promise in Treating Severe Alopecia

Researchers tested the anti-inflammatory drug across two Phase 3 trials involving 1,399 individuals aged 12 to 64. Participants received either 15-milligram or 30-milligram daily doses, with success measured by the Severity of Alopecia Tool (SALT). Those achieving a score of 20 or less—indicating at least 80 percent hair coverage—showed markedly higher rates compared to placebo groups, with the 30-milligram dose yielding up to 55 percent success in one trial.

Improvements emerged as early as eight weeks into the 24-week study period. Beyond clinical measurements, patients reported enhanced quality of life, and serious side effects remained rare. Despite these findings published in JAMA Dermatology, experts maintain a cautious outlook. The trials were funded and co-designed by AbbVie, the drug's manufacturer, and the short 24-week duration leaves questions regarding long-term safety and efficacy. Further independent research is required to weigh the drug's performance against currently available therapies.